Expanding role of lenalidomide in hematologic malignancies
Nilanjan Ghosh, Michael R Grunwald, Omotayo Fasan, Manisha Bhutani Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA Abstract: Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-05-01
|
| Series: | Cancer Management and Research |
| Online Access: | http://www.dovepress.com/expanding-role-of-lenalidomide-in-hematologic-malignancies-peer-reviewed-article-CMAR |
| _version_ | 1818024331740971008 |
|---|---|
| author | Ghosh N Grunwald MR Fasan O Bhutani M |
| author_facet | Ghosh N Grunwald MR Fasan O Bhutani M |
| author_sort | Ghosh N |
| collection | DOAJ |
| description | Nilanjan Ghosh, Michael R Grunwald, Omotayo Fasan, Manisha Bhutani Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA Abstract: Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia. The mode of action includes immunomodulatory, anti-inflammatory, antiangiogenic, and antiproliferative mechanisms. The antitumor effect is a result of direct interference of key pathways in tumor cells and indirect modulation of the tumor microenvironment. There has been no recent collective review on lenalidomide in multiple myeloma, myelodysplastic syndrome/acute myeloid leukemia, and lymphoma. This review summarizes the results of current clinical studies of lenalidomide, alone and in combination with other agents, as a therapeutic option for various hematologic malignancies. Keywords: IMiD, leukemia, lymphoma, myeloma, MDS |
| first_indexed | 2024-12-10T03:58:31Z |
| format | Article |
| id | doaj.art-ecf9c4e6550343df8075637b542990c8 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-10T03:58:31Z |
| publishDate | 2015-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-ecf9c4e6550343df8075637b542990c82022-12-22T02:03:04ZengDove Medical PressCancer Management and Research1179-13222015-05-012015default10511921578Expanding role of lenalidomide in hematologic malignanciesGhosh NGrunwald MRFasan OBhutani MNilanjan Ghosh, Michael R Grunwald, Omotayo Fasan, Manisha Bhutani Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA Abstract: Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia. The mode of action includes immunomodulatory, anti-inflammatory, antiangiogenic, and antiproliferative mechanisms. The antitumor effect is a result of direct interference of key pathways in tumor cells and indirect modulation of the tumor microenvironment. There has been no recent collective review on lenalidomide in multiple myeloma, myelodysplastic syndrome/acute myeloid leukemia, and lymphoma. This review summarizes the results of current clinical studies of lenalidomide, alone and in combination with other agents, as a therapeutic option for various hematologic malignancies. Keywords: IMiD, leukemia, lymphoma, myeloma, MDShttp://www.dovepress.com/expanding-role-of-lenalidomide-in-hematologic-malignancies-peer-reviewed-article-CMAR |
| spellingShingle | Ghosh N Grunwald MR Fasan O Bhutani M Expanding role of lenalidomide in hematologic malignancies Cancer Management and Research |
| title | Expanding role of lenalidomide in hematologic malignancies |
| title_full | Expanding role of lenalidomide in hematologic malignancies |
| title_fullStr | Expanding role of lenalidomide in hematologic malignancies |
| title_full_unstemmed | Expanding role of lenalidomide in hematologic malignancies |
| title_short | Expanding role of lenalidomide in hematologic malignancies |
| title_sort | expanding role of lenalidomide in hematologic malignancies |
| url | http://www.dovepress.com/expanding-role-of-lenalidomide-in-hematologic-malignancies-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT ghoshn expandingroleoflenalidomideinhematologicmalignancies AT grunwaldmr expandingroleoflenalidomideinhematologicmalignancies AT fasano expandingroleoflenalidomideinhematologicmalignancies AT bhutanim expandingroleoflenalidomideinhematologicmalignancies |